PM 359
Alternative Names: PM-359Latest Information Update: 26 Aug 2024
At a glance
- Originator Prime Medicine
- Class Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Neutrophil cytosolic factor 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chronic granulomatous disease
Most Recent Events
- 19 Aug 2024 Prime Medicine plans a phase I/II trial for Chronic granulomatous disease (Treatment experienced) in September 2024 (IV)(NCT06559176)
- 08 May 2024 Pharmacodynamics data from a preclinical trial in chronic granulomatous disease released by Prime Medicine
- 29 Apr 2024 The US FDA approves IND application for PM 359 in Chronic granulomatous disease